Acta Scientific Nutritional Health (ASNH)(ISSN: 2582-1423)

Research Article Volume 6 Issue 7

On the Treatment of Sars-Cov-2 Including Omicron Type

Sorush Niknamian1* and Somayeh Zaminpira2

1Military Medicine Department, Liberty University, Lynchburg, VA, USA
2American Beirut University, Lebanon

*Corresponding Author: Sorush Niknamian, Military Medicine Department, Liberty University, Lynchburg, VA, USA.

Received: January 27, 2022; Published: June 24, 2022

Abstract

Objective: The aim of this research is to introduce new method of the treatment/control of Omicron Virus and answer some major questions regarding the cure of COVID-19 and the new type: Omicron.

Background: We have selected 24 patients (12 females plus 12 males) aged from 15-64 years of old contaminated severe Omicron virus and used the novel methods on the treatment of these patients. Introduction: The Omicron variant (B.1.1.529) is a variant of SARS-CoV-2 which was first reported to the World Health Organization (WHO) from South Africa on 24 November 2021. Omicron multiplies around 70 times faster than the Delta variant in the bronchi but some evidence suggests that it is less severe than previous strains, specifically compared to the Delta variant. Omicron might be less able to penetrate deep lung tissue. Omicron infections are 91 percent less fatal than the delta variant, with 51 percent less risk of hospitalization. Materials and Methods: The Omicron virus has strongly high rate of mutation compared with other kinds of Coronaviruses and therefore, cause severe symptoms of inflammation in the patients including lungs. In our research, all the patients were under unique control. They received HBO2T with 2% Ozone mixture with Oxygen in special cube. Also, they had an injection of liquid ozone which dramatically decline the inflammation in all tissues. They had under strict diet of special Ketogenic diet to maintain their mitochondria to remain high metabolism to hamper the fatigue and tiredness. The had also gain supplements necessary for the disease. Results: all the patient showed full recovery in 3 days, but they had fatigue and tiredness which we had to give them MTC oil 30 grams/day and coconut oil 30 grams/day as well which reduced the tiredness of the patients dramatically and remain their metabolism in a normal state. As a whole, all the patients recovered in 7 days without any symptoms including coughing, tiredness, fever and etc.

Conclusion: Using the novel methodology of the treatment of SARS-CoV including Omicron had positive results on the patients. HBO2T plus specific Ozone therapy dramatically reduced the inflammation in all tissues of the patients. This novel method is a breakthrough in the science of Infectious Diseases including Omicron virus.

Keywords: Omicron Virus; SARS-CoV-2; MTC Oil; Ketogenic Diet; Ozone Therapy; HBO2T Therapy

References

  1. Sexton NR., et al. "Homology-Based Identification of a Mutation in the Coronavirus RNA-Dependent RNA Polymerase That Confers Resistance to Multiple Mutagens". Journal of Virology16 (2016): 7415-7428.
  2. Wertheim JO., et al. “A case for the ancient origin of coronaviruses". Journal of Virology12 (2013): 7039-7045.
  3. Woo PC., et al. “Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the genesource of gammacoronavirus and deltacoronavirus". Journal of Virology7 (2012): 3995-4008.
  4. Bidokhti MR., et al. “Evolutionary dynamics of bovine coronaviruses: natural selection pattern of the spike gene impliesadaptive evolution of the strains". The Journal of General Virology9 (2013): 2036-2049.
  5. Vijgen L., et al. “Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event". Journal of Virology3 (2005): 1595604.
  6. Lau SK., et al. “Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination". Journal of Virology21 (2011): 11325-11337.
  7. Lau SK., et al. “Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications forthe origin of the novel Middle East respiratory syndrome coronavirus". Journal of Virology15 (2013): 8638-8650.
  8. Huynh J., et al. “Evidence supporting a zoonotic origin of human coronavirus strain NL63". Journal of Virology23 (2012): 12816-12825.
  9. Vijaykrishna D., et al. “Evolutionary insights into the ecology of coronaviruses". Journal of Virology8 (2007): 4012-4020.
  10. Gouilh Meriadeg Ar., et al. “SARS-Coronavirus ancestor's foot-prints in South-East Asian bat colonies and the refuge theory". Infection, Genetics and Evolution7 (2011): 1690-1702.
  11. Cui J., et al. “Evolutionary relationships between bat coronaviruses and their hosts". Emerging Infectious Diseases10 (2007): 1526-1532.
  12. “Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern". World Health Organization (2021).
  13. Walls AC., et al. “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein". Cell2 (2020): 281-292.e6.
  14. Niknamian S., et al. “Introducing the Sorush Cancer Treatment Protocol (SCTP)”. Journal of Cancer Research and Clinical Practice 1 (2019): 110.

Citation

Citation: Sorush Niknamian and Somayeh Zaminpira. “On the Treatment of Sars-Cov-2 Including Omicron Type". Acta Scientific Nutritional Health 6.7 (2022): 91-94.

Copyright

Copyright: © 2022 Sorush Niknamian and Somayeh Zaminpira. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.316

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US